Horizon Therapeutics plc announced recently that the U.S. Food and Drug Administration (FDA) has accepted Horizon’s New Drug Application (NDA) for PROCYSBI (Cysteamine Bitartrate) Delayed-Release Oral Granules in Packets
Gotham Therapeutics , a biotechnology company developing a novel drug class targeting RNA-modifying proteins, and Mercachem, the leading European contract research organization, recently announced the generation of a high-quality compound library tailor-made for accelerated hit generation and hit-to-lead expansion against large parts of the epitranscriptomic target space
Arrowhead Pharmaceuticals Inc. recently announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ARO-ANG3 for the treatment of homozygous familial hypercholesterolemia (HoFH)
Gilead Sciences, Inc. and Galapagos NV recently announced that they have entered into a 10-year global research and development collaboration.
From making pain management safer and more effective to identifying inhibitors for a fibrosis target protein and more, researchers from Michigan Medicine, as well as the University of Michigan College of Pharmacy and U-M Life Sciences Institute, are looking to advance their projects through Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards program, which uses AI-powered screening technology employed by large pharmaceutical companies
Abveris, Inc., a global leader in contract research antibody discovery, and Harbour Antibodies H2L2 BV, a wholly-owned subsidiary of Harbour BioMed, recently announced a partnership to offer fully-human antibody discovery service that combines Abveris’ antibody discovery services with the Harbour H2L2 human transgenic mouse platform
Puma Biotechnology, Inc., a biopharmaceutical company, has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for neratinib in combination with capecitabine for the treatment of patients with HER2-positive metastatic breast cancer who have failed two or more prior lines of HER2-directed treatments (third-line disease)
LifeMax Laboratories, Inc. (“LifeMax”), a private company focused on treating rare diseases with few or no therapeutic options, recently announced that the Food & Drug Administration (FDA) granted orphan drug designation to LM-030, an investigational therapy licensed from Novartis and ready to enter into pivotal clinical trials for the treatment of Netherton Syndrome
PeptiDream Inc., a public Kanagawa-based biopharmaceutical company (“PeptiDream”)(TOKYO:4587) announced recently a new Peptide Drug Conjugate “PDC” collaboration agreement with Swiss-based Novartis (“Novartis”)
Gilead Sciences, Inc. and Carna Biosciences Inc recently announced that the companies have entered into a research and development collaboration to develop and commercialize small molecule compounds in immuno-oncology and to access Carna’s proprietary lipid kinase drug discovery platform
|
|
|
|
|
|
|
|
|